Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
The Cancer Letter's weekly podcast of interviews, discussions, and more to dig deep into the issues that shape oncology.
New episodes every Wednesday.
SUBSCRIBE ON
Spotify Apple Podcast YouTube
Spotify Apple Podcast YouTube
on air
In The Headlines: Kimryn Rathmell on loss and caring for our community in uncertain times
Podcast

In The Headlines: Kimryn Rathmell on loss and caring for our community in uncertain times

February 19, 2025
Vol.51 No.06
On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
Black History MonthFreePodcastThe Directors

On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty

February 14, 2025
Vol.51 No.06
By Paul Goldberg
20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect
Cancer History ProjectFreePodcast

20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect

February 14, 2025
Vol.51 No.06
By Yiqing Wang
In The Headlines: Trump moves to cap NIH indirect costs at 15%, HHS agencies webpages removed
Podcast

In The Headlines: Trump moves to cap NIH indirect costs at 15%, HHS agencies webpages removed

February 14, 2025
Vol.51 No.05
A new podcast by The Cancer Letter
Podcast

A new podcast by The Cancer Letter

February 13, 2025

Posts navigation

Previous1…789

Trending Stories

  • FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
    “Patients are owed another review.”
  • Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
  • CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show
  • Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
  • CBER Director Vinay Prasad dared to “say no to drugs”
  • Reforms pending at USPSTF, plus, FDA rejects promising melanoma drug for the second time

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account